A phase 1, open-label, two-group, dose escalation study to investigate the safety, tolerability, biological and clinical activity of EMD 521873 alone and in combination with fixed low doses of cyclophosphamide (CPA) in subjects with advanced solid tumors
Laufzeit: 01.01.2007 - 31.12.2008